Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 16/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275697 | 0.86 | POLB (0.46) | POLBDNMT1CTDSP1TDP1KMT2A | |
| SCHEMBL7002158 | 0.76 | POLB (0.45) | POLBDNMT1CTDSP1TDP1KMT2A | |
| SCHEMBL22275638 | 0.73 | CTSB (0.40) | POLBDNMT1CTDSP1TDP1KMT2A | |
| SCHEMBL6351788 | 0.71 | GUCY1A1 (0.46) | CXCR2 | |
| SCHEMBL6359835 | 0.71 | CXCR2 (0.44) | CXCR2 | |
| SCHEMBL489710 | 0.65 | CXCR2 (0.67) | CXCR2KMT2AMEN1 | |
| SCHEMBL3456686 | 0.65 | CXCR2 (0.44) | CXCR2KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL13980530 | 0.65 | CXCR2 (0.41) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL28010834 | 0.64 | KMT2A (0.54) | CXCR2KMT2AMEN1 | |
| SCHEMBL4373932 | 0.64 | CXCR2 (0.54) | CXCR2CHRM5CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482355-B2 | Asthma, antiallergens; rheumatoid arthritis and atherosclerosis; 2-(Benzylthio)-6-{[(1R)-2-hydroxy-1-methylethyl]amino}-4-pyrimidinol | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1539713-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-12-19 | — | — | EP | disclosed |
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
| EP-1539713-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018435-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | CXCR2, CXCR1, ACKR3 | CXCR2 1/4885CHRM5 2692/4885CX3CR1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.